(PVLA) Palvella Therapeutics - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.639m USD | Total Return: 415.6% in 12m

Genetic Skin, Rare Diseases, Clinical Trials
Total Rating 42
Safety 65
Buy Signal -0.76
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.64B
Avg Turnover: 24.1M
Risk 3d forecast
Volatility82.1%
VaR 5th Pctl12.4%
VaR vs Median-10.1%
Reward TTM
Sharpe Ratio2.33
Rel. Str. IBD96.8
Rel. Str. Peer Group87.3
Character TTM
Beta-0.390
Beta Downside-2.210
Hurst Exponent0.562
Drawdowns 3y
Max DD91.34%
CAGR/Max DD0.23
CAGR/Mean DD0.36

Warnings

Share dilution 487.8% YoY

High Debt/EBITDA (5.1) with thin interest coverage (-17.8)

High Debt while negative Cash Flow

Interest Coverage Ratio -17.8 is critical

Altman Z'' -2.38 < 1.0 - financial distress zone

Choppy Below Avwap Earnings

Tailwinds

Leader

Description: PVLA Palvella Therapeutics

Palvella Therapeutics, Inc. (PVLA) is a clinical-stage biopharmaceutical company. It develops treatments for rare genetic skin diseases. The biotechnology sector is characterized by high research and development costs and long product development cycles.

PVLAs primary candidate, QTORIN 3.9% rapamycin anhydrous gel, is in Phase 3 trials for microcystic lymphatic malformations and Phase 2 for cutaneous venous malformations. The company also explores QTORIN rapamycin for other mTOR-driven skin conditions. Biopharmaceutical companies often rely on a pipeline of drug candidates to sustain growth.

For more detailed financial and operational insights, consider exploring ValueRay.

Headlines to Watch Out For
  • Phase 3 QTORIN trial results impact stock
  • QTORIN approval for microcystic lymphatic malformations
  • QTORIN sales for rare skin diseases
  • Pipeline expansion into new mTOR-driven conditions
Piotroski VR-10 (Strict) 0.0
Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM)
FCF/TA: -0.15 > 0.02 and ΔFCF/TA 11.94 > 1.0
NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev)
CFO/TA -0.11 > 3% & CFO -29.1m > Net Income -49.3m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 28.88 > 1.5 & < 3
Outstanding Shares: last quarter (13.1m) vs 12m ago 487.8% < -2%
Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin)
Asset Turnover: 0.0% > 50% (prev 0.0%; Δ 0.0% > 0%)
Interest Coverage Ratio: -17.78 > 6 (EBITDA TTM -45.6m / Interest Expense TTM 2.56m)
Altman Z'' -2.38
A: 0.96 (Total Current Assets 263.2m - Total Current Liabilities 9.12m) / Total Assets 263.8m
B: -0.57 (Retained Earnings -151.2m / Total Assets 263.8m)
C: -0.27 (EBIT TTM -45.6m / Avg Total Assets 171.6m)
D: -4.81 (Book Value of Equity -151.1m / Total Liabilities 31.4m)
Altman-Z'' = -2.38 = D
What is the price of PVLA shares?

As of May 24, 2026, the stock is trading at USD 115.92 with a total of 165,940 shares traded.
Over the past week, the price has changed by -0.22%, over one month by -12.74%, over three months by +29.77% and over the past year by +415.56%.

Is PVLA a buy, sell or hold?

Palvella Therapeutics has received a consensus analysts rating of 4.78. Therefore, it is recommended to buy PVLA.

  • StrongBuy: 7
  • Buy: 2
  • Hold: 0
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the PVLA price?
Analysts Target Price 229 97.6%
Palvella Therapeutics (PVLA) - Fundamental Data Overview as of 24 May 2026
P/B = 7.4884
Revenue TTM = 0.0 USD
EBIT TTM = -45.6m USD
EBITDA TTM = -45.6m USD
Long Term Debt = 375k USD (estimated: total debt 584k - short term 209k)
Short Term Debt = 209k USD (from shortTermDebt, last quarter)
Debt = 1.22m USD (from shortLongTermDebtTotal, last quarter) + Leases 633k
Net Debt = -231.7m USD (calculated: Debt 1.22m - CCE 232.9m)
Enterprise Value = 1.41b USD (1.64b + Debt 1.22m - CCE 232.9m)
Interest Coverage Ratio = -17.78 (Ebit TTM -45.6m / Interest Expense TTM 2.56m)
EV/FCF = -35.81x (Enterprise Value 1.41b / FCF TTM -39.3m)
FCF Yield = -2.79% (FCF TTM -39.3m / Enterprise Value 1.41b)
 FCF Margin = unknown (Revenue TTM is 0 or missing)
 Net Margin = unknown
 Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
 Tobins Q-Ratio = 5.33 (Enterprise Value 1.41b / Total Assets 263.8m)
 Interest Expense / Debt = 210.7% (Interest Expense 2.56m / Debt 1.22m)
 Taxrate = 21.0% (US default 21%)
NOPAT = -36.0m (EBIT -45.6m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 18.08 (Total Current Assets 263.2m / Total Current Liabilities 14.6m)
Debt / Equity = 0.01 (Debt 1.22m / totalStockholderEquity, last quarter 232.3m)
 Debt / EBITDA = 5.08 (negative EBITDA) (Net Debt -231.7m / EBITDA -45.6m)
 Debt / FCF = 5.90 (negative FCF - burning cash) (Net Debt -231.7m / FCF TTM -39.3m)
 Total Stockholder Equity = 86.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -28.73% (Net Income -49.3m / Total Assets 263.8m)
RoE = -20.72% (Net Income TTM -49.3m / Total Stockholder Equity 237.9m)
RoCE = -19.13% (EBIT -45.6m / Capital Employed (Equity 237.9m + L.T.Debt 375k))
 RoIC = -164.0% (out of range, set to none) (NOPAT -36.0m / Invested Capital 22.0m)
 WACC = 4.61% (E(1.64b)/V(1.64b) * Re(4.61%) + (debt cost/tax rate unavailable))
Discount Rate = 4.61% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 185.3%
 [DCF] Fair Price = unknown (Cash Flow -39.3m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.11 | # QB: 0
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: N/A | # QB: 0
EPS current Quarter (2026-06-30): EPS=-1.18 | Chg30d=-12.55% | Revisions=-33% | Analysts=13
EPS next Quarter (2026-09-30): EPS=-1.48 | Chg30d=-6.38% | Revisions=+0% | Analysts=13
EPS current Year (2026-12-31): EPS=-5.61 | Chg30d=-9.20% | Revisions=-41% | GrowthEPS=-51.3% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-6.72 | Chg30d=-2.23% | Revisions=-14% | GrowthEPS=-19.8% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -41%